Destiny Pharma

Executive Summary

Destiny Pharma, operating under the brand AMR Bio, is a clinical-stage biotechnology company focused on developing novel anti-infective therapies to combat antimicrobial resistance (AMR). The company's strategy centers on infection prevention, building strong clinical data packages for its proprietary assets, and then seeking partners for late-stage development and commercialization. Although the company operates in a high-need area with significant market potential, its pipeline details remain limited in public disclosures. The company's progress hinges on advancing its lead candidates through clinical trials and securing strategic partnerships, which would validate its technology and provide non-dilutive funding.

Upcoming Catalysts (preview)

• H2 2026Phase 2 data readout for lead candidate55% success
• 2026Announcement of licensing or partnership deal50% success
• Q3 2026Initiation of new clinical trial45% success